News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Inotek Pharmaceuticals Corporation's Novel Glaucoma Candidate, INO-8875, Significantly Reduces Intraocular Pressure in Phase 1/2 Study



6/25/2009 8:51:05 AM

LEXINGTON, Mass.--(BUSINESS WIRE)--Inotek Pharmaceuticals today announced positive top-line results from a Phase 1/2 randomized, double-blind, placebo-controlled clinical trial of the Company’s lead candidate, INO-8875, in patients with glaucoma. Treatment with INO-8875 was well tolerated and resulted in a statistically significant reduction in intraocular pressure (IOP). Elevated IOP can be a risk factor in the development and progression of optic nerve changes and vision loss associated with glaucoma and is thought to be a causal factor in the neuropathology of the disease. INO-8875 represents a new approach to treating glaucoma patients by increasing the outflow of ocular fluid via the trabecular meshwork, the main pathway used by healthy eyes to maintain normal IOP.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES